FDA Approves First Generic Baloxavir, Broadening Access to Single-Dose Flu Treatment

Norwich Pharmaceuticals received FDA approval on June 17, 2026 for the first generic baloxavir marboxil — a single-dose oral influenza antiviral — opening competition with Roche's branded Xofluza for the first time.

FDA & Regulatory Desk Friday, 19 June 2026 · 2 min read

The U.S. Food and Drug Administration approved the first generic version of baloxavir marboxil — a single-dose oral influenza antiviral — on June 17, 2026, via an abbreviated new drug application (ANDA) filed by Norwich Pharmaceuticals, according to an FDA press announcement (FDA-PR-2026-06-17-generic-baloxavir). FDA uses the term “approved” for drug ANDAs; “cleared” is the terminology for medical devices under the 510(k) pathway.

Baloxavir marboxil is the active moiety of Xofluza, licensed by Genentech/Roche in the United States since 2018 for the treatment of acute uncomplicated influenza in patients 12 years and older (and expanded to high-risk patients in October 2019, based on the CAPSTONE-2 trial). Baloxavir inhibits the cap-dependent endonuclease of the influenza polymerase acidic (PA) subunit — a mechanism distinct from the neuraminidase inhibitors (oseltamivir, zanamivir, peramivir). Single-dose oral administration differentiates it from the twice-daily five-day regimens of neuraminidase inhibitors.

Generic entry and access implications

Generic entry typically results in price decreases of 80–90% for small-molecule drugs within two to three years of competition. Xofluza carries a list price in excess of $150 per single dose in the United States; generic baloxavir is expected to enter at a substantially lower price point, expanding access for patients who either lack prescription drug coverage or face high cost-sharing.

The FDA approval also has implications for antiviral stockpiling. The U.S. Strategic National Stockpile maintains influenza antiviral reserves; generic availability lowers the per-course cost of maintaining baloxavir reserves, which are relevant in the context of pre-pandemic preparedness.

Resistance context

Baloxavir carries a class-labeling note regarding the PA/I38T substitution, which confers reduced susceptibility and has been detected in some treated patients, particularly children, in post-marketing surveillance. The prescribing information for the generic is expected to carry the same warnings and contraindications as the reference product. No labeling changes specific to resistance were announced with this approval.

Correction (2026-06-19): Two errors corrected by post-publication fact-check. (1) The headline and dek used “FDA Clears” — terminology specific to medical devices under the 510(k) pathway — for a pharmaceutical ANDA drug approval; the FDA’s own press release uses “Approves.” The article has been corrected throughout to use “approved/approval.” (2) Baloxavir marboxil was expanded to high-risk patients in October 2019 (CAPSTONE-2 trial), not 2021 as stated; no documented Xofluza supplemental approval milestone occurred in 2021.

Trace · every claim, sourced

Reported and written by FDA & Regulatory Desk, then each load-bearing claim was bound to the primary source it rests on and checked out-of-band against that source before publication. The full mapping is below — nothing here is taken on faith.

FDA approved the first generic baloxavir marboxil (ANDA filed by Norwich Pharmaceuticals) on June 17, 2026.

fda_press_release FDA Approves First Single-Dose Generic Treatment for Influenza — June 17, 2026 FDA-PR-2026-06-17-generic-baloxavir

Baloxavir marboxil (branded Xofluza) has been licensed in the U.S. since 2018 for acute uncomplicated influenza, with a single oral dose regimen distinguishing it from neuraminidase inhibitors.

fda_press_release FDA Approves First Single-Dose Generic Treatment for Influenza — June 17, 2026 FDA-PR-2026-06-17-generic-baloxavir

After publication, a separate AI panel re-verifies every edition against these same sources. The running claim-confirmation rate and every correction are public on the accuracy ledger.